Guggenheim Reiterates Spyre (SYRE) at Buy, 'optimistic that the company is best-positioned to pioneer longer-acting mAb therapeutics in IBD'
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $65.00 price target on Spyre (NASDAQ: SYRE).The analyst commented: "Ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
